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Hearingtherefore, tested the hypothesis that aspirin could also reduce ototoxicity from cisplatin-based
chemotherapy.
Methods: A total of 94 patients receiving cisplatin-based chemotherapy for multiple cancer
types were recruited into a phase II, double-blind, placebo-controlled trial and randomised
in a ratio of 1:1 to receive aspirin 975 mg tid and omeprazole 20 mg od, or matched placebos
from the day before, to 2 days after, their cisplatin dose(s), for each treatment cycle. Patients
underwent pure tone audiometry before and at 7 and 90 days after their final cisplatin dose.
The primary end-point was combined hearing loss (cHL), the summed hearing loss at 6 kHz
and 8 kHz, in both ears.
Results: Although aspirin was well tolerated, it did not protect hearing in patients receiving
cisplatin (p-value Z 0.233, 20% one-sided level of significance). In the aspirin arm, patients
demonstrated mean cHL of 49 dB (standard deviation [SD] 61.41) following cisplatin
compared with placebo patients who demonstrated mean cHL of 36 dB (SD 50.85). Women
had greater average hearing loss than men, and patients treated for head and neck malignancy
experienced the greatest cHL.
Conclusions: Aspirin did not protect from cisplatin-related ototoxicity. Cisplatin and genta-
micin may therefore have distinct ototoxic mechanisms, or cisplatin-induced ototoxicity
may be refractory to the aspirin regimen used here.
ª 2017 The Authors. Published by Elsevier Ltd. This is an open access article under the CC
BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Cisplatin is a commonly used cytotoxic chemothera-
peutic agent to treat a wide variety of cancer types,
including head and neck, bladder, lung and germ-cell
malignancies. In each of these diseases, cisplatin is used
in curative as well as palliative treatment settings. Sub-
sequently, adverse effects of treatment which are irre-
versible will potentially impact on patients for prolonged
periods of time, thereby reducing health-related quality-
of-life. Cisplatin has well-documented side-effects,
including one of the highest rates of ototoxicity of all
chemotherapy agents [1,2]. Cisplatin-related ototoxicity
includes high-frequency bilateral and symmetrical hear-
ing loss, which may be permanent and irreversible and is
often associated with tinnitus [2,3]. Currently, there are
no established methods to avoid or reverse cisplatin-
related ototoxicity, other than dose reduction or
switching to non-cisplatin regimens, which can have
negative impacts on outcomes. Hence, ototoxicity risk
must be weighed against oncological efficacy.
Fifty percent of patients receiving a cumulative
cisplatin dose of>200 mg/m2 have a significant reduction
in their hearing, with a severe to profound hearing loss in
both ears [2,4e6]: Using the American SpeecheLan
guageeHearing Association criteria, this equates
to> 71 dB hearing loss, which clinically translates into the
patient being aware of their hearing loss in most, if not all
situations and onlymanagingwithout a hearing aid if they
concentrate and the speaker significantly raises their voice
and if there are no competing sound sources [2].Clearly,
this degree of hearing loss is very debilitating andmay notalways be appreciated by the clinician, on a one-to-one
basis [7].
Ototoxicity from cisplatin is thought to be due, in
part, to reactive oxygen species (ROS); ROS can be
attenuated by antioxidants, such as salicylates, including
aspirin. Gentamicin and cisplatin are thought to have a
similar ototoxic mechanism of action. ROS lead to S-
Nitrosylation of cochlear proteins causing damage to
the outer hair cells, supporting cells, marginal cells of
the stria vascularis, spiral ligament and the spiral gan-
glion cells [8]. The outer hair cells in the basal turn of the
cochlea are the most affected [9,10], resulting in an
initial elevation of high-frequency audiometric thresh-
olds, followed by a progressive loss into the lower fre-
quencies with continued therapy [11].
Aspirin was shown to prevent gentamicin-induced
hearing loss without compromising its anti-bacterial
efficacy in both animal models and in the clinical
setting [12,13]. Patients treated with 1 g tds aspirin for 14
days, in addition to gentamicin, as part of a randomised
controlled trial (RCT), showed a significant reduction in
hearing loss compared with patients receiving genta-
micin alone [12]. The incidence of significant hearing
loss reduced from 13% in the placebo arm to 3% in the
aspirin arm (relative risk 0.26, 95% confidence interval
[CI] 0.08e0.86).
Aspirin has also been shown to protect hearing from
cisplatin-induced ototoxicity in rats, using a breast cancer
model [14]. Protection of hearing was achieved without
apparent loss of anti-tumour efficacy of cisplatin.
We, therefore, sought to test if aspirin could reduce
cisplatin-related hearing loss in a phase II RCT for
S.J. Crabb et al. / European Journal of Cancer 87 (2017) 75e83 77patients treated with a variety of cisplatin-based sys-
temic anti-cancer therapy regimens.2. Patients and methods
We performed a phase II RCT in patients receiving
cisplatin-based chemotherapy in eight United Kingdom
cancer centres.
Patients were eligible if they were 18 years or older
and deemed suitable for a chemotherapy regimen con-
taining a cumulative cisplatin dose of 200 mg/m2, with
a maximum of two consecutive days cisplatin dosing per
cycle, either as a single agent or as a combination
chemotherapy. Key exclusion criteriaincluded were as
follows: prior cisplatin treatment; diagnosis of naso-
pharyngeal or skull base carcinoma (other head and neck
tumours allowed); treatment plan requiring cisplatin for
more than two or on non-consecutive days of a treatment
cycle; therapeutic aspirin >75 mg/day; prior history of
haemorrhagic stroke, inflammatory bowel disease or
haematological clotting disorders; absolute contraindi-
cation to aspirin/proton-pump inhibitors; symptomatic
hearing loss which the PI considered excluded the use of
cisplatin; pregnant/breast-feeding patients. Women of
childbearing potential were required to have a negative
pregnancy test performed within 7 days before trial drug
administration, and all patients were required to use
adequate birth control.
Baseline hearing tests were recorded before receiving
the first cisplatin dose and included pure tone audiom-
etry (PTA) and otoacoustic emissions (OAEs). A new
technique has enabled non-linear components of the
OAE to be recorded [15], showing that both second- and
third-order non-linear components (Volterra Kernels),
vk21evk23 and vk31evk33, are much more sensitive to
minor hearing system damage than conventionally
recorded responses [16]. These were repeated for 7 days
(3 days) after completion of the last cisplatin dose and
again at 90 days (7 days) after treatment.
Patients received up to six cycles of cisplatin-based
chemotherapy, according to tumour site, response and
toxicity. Aspirin at a dose of 975 mg tid, or placebo were
administered orally, for 4 days in patients receiving
cisplatin on a single day each cycle and for 5 days in
patients receiving fractionated cisplatin chemotherapy
on two consecutive days of each cycle (commencing the
day before the first cisplatin administration, in both
cases, to protect the hair cells from the cisplatin until it
is bound to the plasma proteins or cleared via the kid-
neys). Omeprazole 20 mg or matching placebo was
taken orally, once daily on the same days as the aspirin/
placebo (i.e. patients received either both drugs or both
placebos).
Blinding to drug/placebo allocation was achieved by
formulation of a 975-mg enteric-coated aspirin tablet
with a matched placebo. Omeprazole was sourced fromthe commercial market and over encapsulated using an
opaque gelatin capsule. A matched placebo for the
omeprazole tablet was also over encapsulated (NuPharm
Laboratories Ltd, Flintshire, UK).
The primary outcome was change in hearing loss
during treatment (measurements taken before and at 7
days and 3 months after completion of cisplatin treat-
ment) using PTA test at frequencies of 6 kHz and 8 kHz
in both ears. Secondary outcome measures included
assessment of other PTA test frequencies including 0.25,
0.5, 1, 2, 3 and 4 kHz at baseline and at 7 days and 3
months post-cisplatin; clinician-assessed level of hearing
loss measured by the Common Toxicity Criteria for
Adverse Events (CTCAE), version 4.03; OAE profile
before and after treatment (at 7 days and 3 months post-
cisplatin); safety profile assessment using CTCAE and
with specific focus on gastrointestinal and renal toxicity;
assessment of treatment and concomitant medication
compliance and cisplatin dose intensity.
Trial conduct was in accordance with the principles
outlined in the International Conference on Harmo-
nisation Good Clinical Practice guidelines and in
compliance with the protocol, the Data Protection Act
and all other ethical and regulatory requirements, as
appropriate. Written informed consent was obtained
from all study participants. The trial was sponsored by
University Hospital Southampton NHS Foundation
Trust and coordinated by the Southampton Clinical
Trials Unit. Funding was from Cancer Research UK
(C39812/A13344). EudraCT reference number: 2012-
001509-25.
3. Statistical methods
The primary outcome was combined hearing loss (cHL)
in decibels, assessed as total post-treatment hearing after
chemotherapy (the sum of PTA measurements at 6 kHz
and 8 kHz in both ears at the first time point after their
last cisplatin dose), adjusted for baseline total hearing.
This was assessed in the intention-to-treat (ITT) cohort
using an analysis of covariance (ANCOVA) model
adjusted for treatment arm and the stratification factor
cisplatin dose. In addition, a ‘per-protocol cohort’
analysis and ‘protected cisplatin cohort’ (each cisplatin
cycle received was ‘protected’ by either aspirin or pla-
cebo) analyses were planned as secondary outcomes.
Supplementary Document 1 provides full details of
the sample size. A total of 88 patients (44 per arm) were
required, allowing for 80% power with a one-sided sig-
nificance level of 20%. Patients were randomised using a
web-based system on a 1:1 allocation, using block ran-
domisation stratified by cisplatin dose.
4. Results
A total of 439 patients were screened to allow 94 pa-
tients to be recruited to the trial (45 to aspirin and 49 to
S.J. Crabb et al. / European Journal of Cancer 87 (2017) 75e8378placebo): a reflection of block randomisation. Patients
were recruited between 14-March-2013 and 09-July-
2015, and were followed up for 3 months. The trial
ended when a sufficient number of patients with baseline
and at least one post-chemo PTA test were available.Fig. 1. CONSORT diagram for cisplatin ototoxicity attenuaReasons for screen failure are detailed in Fig. 1. De-
mographic characteristics (age, gender and ethnicity)
and hearing at baseline were balanced between arms
(Table 1). Planned and actual cisplatin dose adminis-
tered were also balanced between arms; however, someted by aspirin trial (intent-to-treat population, n Z 94).
Table 1
Patient demographics and tumour groups (intent-to-treat population,
n Z 94).
Characteristic Aspirin
(n Z 45)
Placebo
(n Z 49)
Age at randomisation
Mean (SD) 56.1 (11.20) 60.0 (11.78)
Range 24.0e75.0 27.0e79.0
Gender: n (%)
Female 9 (20.0%) 13 (26.5%)
Male 36 (80.0%) 36 (73.5%)
Ethnicity: n (%)
White 43 (95.6%) 48 (98.0%)
Asian or Asian British 0 1 (2.0%)
Black or black British 1 (2.2%) 0
Not stated 1 (2.2%) 0
Total baseline hearinga
N 45 48
Mean (SD) 164.9 (70.93) 170.2 (85.88)
Range 5.0 to 295.0 40.0e385.0
Planned cisplatin dose level: n (%)
>200 mg/m2 but <300 mg/m2 22 (48.9%) 24 (49.0%)
>300mg/m2 but <400 mg/m2 11 (24.4%) 13 (26.5%)
>400 mg/m2 12 (26.7%) 12 (24.5%)
Actual cisplatin dose level: n (%)
>200 mg/m2 but <300 mg/m2 22 (48.9%) 22 (44.9%)
>300 mg/m2 but <400mg/m2 12 (26.7%) 13 (26.5%)
>400 mg/m2 11 (24.4%) 14 (28.6%)
Tumour group: n (%)
Bladder carcinoma 8 (17.8%) 15 (30.6%)
Germ cell 7 (15.6%) 5 (10.2%)
Head and neck 21 (46.7%) 14 (28.6%)
Lung 9 (20.0%) 15 (30.6%)
Number of patients who withdrew
before treatment: n (%)
2 (4.4%) 1 (2.0%)
Number of patients who completed
plannedb treatment: n (%)
23 (51.1%) 25 (51.0%)
SD, standard deviation.
a Total baseline hearing is the sum of pure tone audiometry mea-
surements at 6 kHz and 8 kHz in both ears before their first cisplatin
dose.
b Planned treatment regimen (number of cisplatin cycles) as on
baseline electronic Case Report Form (eCRF).
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(Table 1). There were trends of more bladder tumours in
the placebo arm (15 versus 8) and more head and neck
tumours in the aspirin arm (21 versus 14). Median inter-
cycle time was the same between both arms (21 days)
and there were similar doses of cisplatin received and
cisplatin dose intensity between the arms (data not
shown). Of note, gastrointestinal problems reported at
baseline were greater in the placebo arm (22% versus
4%).
Patient follow-up is shown in Supplementary Table 1,
detailing per-protocol and cisplatin-protected groups: 32
(71%) of the aspirin arm and 34 (69%) of the placebo
arm attended both follow-up visits for PTA and OAE
testing. Twenty-four patients also underwent OAE
testing at baseline (aspirin: 9 and placebo: 15), which
showed a bigger range of OAE in the placebo arm, but
this was not significant (data not shown).There was a difference between one or more days
delay in chemotherapy administration between the arms
15 of 45 (33.3%) for the aspirin arm compared with 21 of
49 (42.9%) for placebo, resulting in 19 and 30 delayed
cisplatin cycles, respectively. The individual reasons are
outlined in Supplementary Table 2. Reasons for patients
stopping treatment early are outlined in Supplementary
Table 3 and show that these were similar between both
arms.
Up to 75 mg per day of therapeutic aspirin was
permitted for trial entry: Four patients (8%) of the
placebo arm and six patients (13%) of the aspirin arm
were taking up to 75 mg of aspirin at baseline: this had
dropped to one patient for both arms at follow-up.
4.1. Primary end-point
The primary end-point was cHL at 6 kHz and 8 kHz. In
the ITT population, there was a mean cHL of 49.0 dB
(n Z 39; standard deviation [SD] 61.41) and 36.0 dB
(n Z 40; SD 50.85) in the aspirin and placebo arms,
respectively. In the ANCOVA model, total post-
treatment hearing was compared between the two arms
after adjusting for total hearing at baseline and cisplatin
dose level. There was no evidence to suggest that aspirin
protects hearing (least squares mean difference Z 9.38
[60% CI: 1.45 to 20.22; p-valueZ 0.233 at a 20% one-
sided level of significance]; Table 2).
No evidence of statistically significant differences in
total post-treatment hearing between aspirin and pla-
cebo arms was observed in the per-protocol or protected
cisplatin populations (p-values Z 0.300 and 0.344,
respectively at a 20% one-sided level of significance; data
not shown).
4.2. Secondary end-points
At 90 days after completion of cisplatin chemotherapy,
the cHL remained in the aspirin arm with a mean loss of
63.9 dB (n Z 27; SD 52.59) and 37.3 dB (n Z 30; SD
49.94) in the placebo arm. It can be seen (Fig. 2) that
there was no substantial change in the cHL between
days 7 and 90 (correlation coefficient equal to 0.95 [i.e.
day 7 and day 90]). Hearing loss does not correlate with
cisplatin dose (200 mg/m2 but <300 mg/m2, 300 mg/
m2 but <400 mg/m2 or 400 mg/m2). Additional ad hoc
analysis, dividing patients at baseline into normal and
mild hearing and moderate or worse hearing showed
that the better the initial hearing, the greater the sub-
sequent hearing loss (Supplementary Fig. 1). However,
there was no difference in ototoxic protection between
these different hearing groups with aspirin or placebo
(data not shown). In addition, age did not predict for
hearing loss in these data although the sample size may
preclude meaningful conclusion. In our data set, women
lost more hearing than men (Supplementary Fig. 2)
and patients receiving cisplatin for head and neck
Table 2
Analysis of covariance of combined hearing loss (first post-chemotherapy pure tone audiometry hearing test) (intent-to-treat population, nZ 79).
Characteristic Statistic
Least squares means Estimate Difference 60% CI of LS mean One-sided p-valuea
Aspirin (n Z 39) 218.80 9.38 (1.45 to 20.22) 0.233
Placebo (n Z 40) 209.40
Model coefficients Estimate 60% CI Two-sided p-value
Aspirin arm 9.38 (1.45 to 20.22) 0.466
Placebo arm 0 (Ref) e e
Intercept 61.22 (42.90e79.54) 0.006
Total hearing at baseline 0.85 (0.78e0.92) <0.001
Dose level: 200 mg/m2 but <300 mg/m2 7.48 (5.58 to 20.54) 0.629
Dose level: 300 mg/m2 but <400 mg/m2 2.23 (17.20 to 12.74) 0.900
Dose level: 400 mg/m2 0 (Ref) e e
CI, confidence interval; ANCOVA, analysis of covariance; LS, least squares; PTA, pure tone audiogram.
a Combined hearing loss assessed using ANCOVA model: Total post-treatment hearing post-chemotherapy (the sum of PTA measurements at
6 kHz and 8 kHz in both ears at the first time point after their last cisplatin dose) Z intercept þ treatment arm þ total hearing at baseline (the
sum of PTA measurements at 6 kHz and 8 kHz in both ears before their first cisplatin dose) þ randomisation stratification factor dose of
cisplatin.
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(Supplementary Fig. 3). OAE data confirm the PTA
data (Supplementary Table 4).
4.3. Safety end-points
From the ITT population, 88.9% (40 of 45) of aspirin
and 95.9% (47 of 49) of placebo patients experienced at
least one adverse event (Supplementary Table 5). Renal
toxicity affected more patients in the aspirin arm (17.8%
versus 10.2%) although the majority of these wereFig. 2. Scatter plot to assess the relationship between the first and seco
population provided two post-chemotherapy values, n Z 57).CTCAE, version 4.03, grade I or II (Supplementary
Table 6): By contrast, renal and serum biochemistry
values did not appear to be altered by the administration
of aspirin or placebo (Supplementary Table 7).
Interestingly, reported gastrointestinal toxicities were
similar between arms; supporting the use of proton
pump inhibitors to minimise any gastrointestinal toxic-
ities. In addition, hearing toxicities were greater in the
placebo arm (44.9% versus 28.9%; Table 3).
There were 20 of 22 (90.9%) and 22 of 24
(91.7%) aspirin and placebo arm patients, respectively,nd pure tone audiometry hearing assessment values (intent-to-treat
Table 3
Hearing toxicity experienced during the trial period by CTCAE grade
(intent-to-treat population, n Z 94).
Characteristic Aspirin
(n Z 45)
Placebo
(n Z 49)
Number of patients who experienced
at least one hearing AE: n (%)a
13 (28.9%) 22 (44.9%)
Hearing adverse events: n (%)a
CTCAE, version 4.03 grade I or II 13 (28.9%) 22 (44.9%)
CTCAE, version 4.03 grade III or
above
0 0
Severe, life-threatening or death-related
hearing adverse events (CTCAE,
version 4.0 grade III or above): n (%)a
0 0
Inner ear toxicity 0 0
AE, adverse event; CTCAE, Common terminology criteria for adverse
events.
a If a patient experienced more than one hearing AE with different
CTCAE grades, then the worst CTCAE grade is counted in this table.
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only two patients were reported as experiencing serious
adverse reactions (SARs).
5. Discussion
Aspirin was well tolerated but did not protect hearing in
patients when combined with cisplatin chemotherapy.
Aspirin was protective in a prior study of patients
receiving gentamicin (although describing a different
primary end-point), suggesting that either cisplatin and
gentamicin have distinct ototoxic mechanisms (and
aspirin would not have been protective at any dose) or
cisplatin in the cumulative doses required for most
cancer indications, is perhaps more ototoxic, requiring
larger (and potentially impractical) or prolonged pro-
tective doses [12]. As an antimicrobial agent, gentamicin
is expected to reach a relatively steady state in contrast
with cisplatin, which relies on a maximally tolerated
dose; which leads us to the possibility that perhaps an
increased aspirin dose to compensate for this would
have provided ototoxic protection. In addition, the
question of aspirin-related ototoxicity should be raised
although it is unlikely to result in any permanent or
irreversible ototoxicity at the short duration adminis-
tered in this trial [17]. With regard to duration of aspirin
administration, we chose to evaluate a 4- or 5-day
schedule starting 24 h prior, until 2 days after, cisplatin
on each cycle. The rationale for this approach was to
optimise aspirin exposure to the duration of peak
cisplatin exposure. The clearance of total platinum from
plasma is rapid during the first 4 hours after intravenous
administration and decays monoexponentially with a
half-life of about 20e30 minutes following bolus ad-
ministrations of 50 or 100 mg/m2 doses. However, there
is then a prolonged low exposure to plasma proteine-
bound platinum that may persist for many years after
cisplatin administration and might potentially accountfor a failure to address acute ototoxicity through the
approach tested here [18e20].
It is interesting that, despite the negative PTA and
OAE (Supplementary Table 4) results, hearing toxicity,
as perceived by patients, was significantly worse in the
placebo arm (Table 3). At this time, PTA is the gold
standard for quantifying hearing loss. However, we
accept that it does not capture qualitative, patient-related
outcome, and this may explain the reported differences.
Our data did not show any significant deterioration in
the acute setting between day 7 and day 90 (Fig. 2). This
contrasts with previously published data that have shown
increased hearing loss after completion of cisplatin over a
chronic time course over many months and years, which
has been explained by the long-term (up to 20 years)
retention of this compound [19,20]. It is feasible that
continued follow-up of our patient cohort could have
demonstrated this chronic continued deterioration that
we did not identify in the acute setting.
Patients with better hearing at baseline were at greater
relative risk of hearing loss following cisplatin
(Supplementary Fig. 1). This is likely to reflect the
number of functional hair cells that can potentially be
destroyed by cisplatin in those patients with good hear-
ing [14]. This may be important clinically as cisplatin
might tend to be avoided, based on treatment guidelines,
in patients with pre-existent poor hearing to minimise the
risk of further deterioration. However, the greatest risk
of harm, in absolute terms, may in fact reside with those
patients with good hearing initially. This is perhaps
counterintuitive to many clinicians in their approach to
the use of cisplatin in routine practice, and guidelines
should be considered for this patient group.
Women suffered greater hearing loss than men
(Supplementary Fig. 2). Previous papers have published
hearing loss data associated with cisplatin in discrete
disease types (i.e. gynaecological and testicular cancers)
where gender differences would not have been high-
lighted [21,22]. However, a rat model supports our
gender difference by demonstrating adult female rat
predisposition to increased cisplatin toxicity: this resulted
in an increased audiometric loss and histopathological
correlation, reflecting increased damage in the spiral
ganglion and brainstem of female rats [23]. By contrast,
in the paediatric population, boys are four times more
likely to suffer from cisplatin-induced ototoxicity than
girls, perhaps reflecting hormonal protection [24].
It is well established that an increasing dose of
cisplatin is associated with an increasing risk of
ototoxicity [11]. In contrast to this and to the data
recently published [2], cisplatin dose in our cohort did
not correlate with ototoxic potential. In the Frisina
germ-cell cohort, greater or less than 300 mg/m2
cisplatin stratified patients into severity of hearing loss
[2]. It is likely that our smaller sample size, across
multiple tumour types, contributed to this lack of effect.
S.J. Crabb et al. / European Journal of Cancer 87 (2017) 75e8382We demonstrated that head and neck cancer
patients experienced the largest median hearing loss
(Supplementary Fig. 3): This may have resulted from the
concomitant radiotherapy that this patient population
would also have received, which despite cochlear sparing
(Intensity Modulated Radiotherapy, IMRT) protocols,
may still induce a degree of cochlear damage [25,26].
Although this is unlikely to have introduced significant
bias into the trial, it is important to highlight that there
were more head and neck patients in the aspirin arm and
more bladder patients in the placebo arm. Despite being
a younger cohort with better baseline hearing, germ-cell
patients surprisingly did not show worse hearing loss
(Supplementary Fig. 3).6. Conclusion
Although aspirin was well tolerated, it did not protect
hearing at the doses and in the schedule investigated here,
suggesting that cisplatin and gentamicin may have
distinct ototoxic mechanisms or that cisplatin is more
ototoxic, requiring larger protective doses. Qualitative
data did suggest a protective effect of aspirin, but this trial
was not powered to test this hypothesis. Cisplatin-
induced ototoxicity results in significant morbidity, and
further research is required to devise options to prevent it.Conflict of interest statement
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